

Vol 3, No 2 (2011)

Mol Cell Pharmacol

Table of Contents

PharmSights

Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks – A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes	ABSTRACT PDF
<i>Po-Hsien Huang, Christoph Plass, Ching-Shih Chen</i>	39-43
Functional Roles of Endothelin ETB Receptor in the Vascular Disease and Its Sex Difference	ABSTRACT PDF
<i>Kento Kitada, Mamoru Ohkita, Yasuo Matsumura</i>	45-52
Bladder Selectivity of Imidafenacin, a Novel Antimuscarinic Agent Developed to Treat Overactive Bladder	ABSTRACT PDF
<i>Shizuo Yamada, Akira Yoshida, Masaki Ogoda, Yusuke Fuchihata, Shiori Kuraoka, Hideo Tsukada, Tsuyoshi Anraku</i>	53-58
Precise Synchrony by Mutual Inhibition: Experiments Vindicate Theory	ABSTRACT PDF
<i>Hang Hu, Yunyong Ma, Ariel Agmon</i>	59-65
Novel Insights into Beneficial Consequences of Statins in Sepsis: Anti-inflammatory and Anti-apoptotic Mechanisms	ABSTRACT PDF
<i>Kengo Tomita, Ken-ichi Takano, Hiroki Yokoo, Yuichi Hattori</i>	67-74

FDA Corner

FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor	ABSTRACT PDF
	75
FDA Approves Erwinaze to Treat a Form of Leukemia	ABSTRACT PDF
	75-76
FDA Approves Cialis to Treat Benign Prostatic Hyperplasia	ABSTRACT PDF
	76
FDA Approves Remicade to Treat Ulcerative Colitis in Children 6 Years and Older	ABSTRACT PDF
	76-77